Biogen Inc. diskutieren
Biogen Inc.
WKN: 789617 / Symbol: BIIB / Name: Biogen / Aktie / Pharmazeutika / Large Cap /
178,38 €
-0,92 %
Biogen (BIIB) had its "buy" rating reaffirmed by Needham & Company LLC.
Ratings data for BIIB provided by MarketBeat
Biogen (BIIB) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Ratings data for BIIB provided by MarketBeat
Biogen (BIIB) had its price target raised by Needham & Company LLC from $255.00 to $256.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen (BIIB) had its "reduce" rating reaffirmed by HSBC Holdings plc.
Ratings data for BIIB provided by MarketBeat
Biogen (BIIB) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Ratings data for BIIB provided by MarketBeat
Biogen (BIIB) was given a new $235.00 price target by Truist Financial Corporation. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen (BIIB) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Ratings data for BIIB provided by MarketBeat
Biogen (BIIB) had its "overweight" rating reaffirmed by Piper Sandler.
Ratings data for BIIB provided by MarketBeat
Neueste Beiträge
Bank_of_America_Co_ in Booz Allen Hamilton A diskutieren